Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

@article{Bardy2005AmiodaroneOA,
  title={Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.},
  author={Gust H. Bardy and Kerry Lamont Lee and Daniel B. Mark and Jeanne E. Poole and Douglas L. Packer and Robin Boineau and Michael J. Domanski and Charles Troutman and Jill Anderson and George W. Johnson and Steven E. McNulty and Nancy E. Clapp-Channing and Linda D Davidson-Ray and Elizabeth S. Fraulo and Daniel P. Fishbein and Richard M. Luceri and John Ip},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 3},
  pages={
          225-37
        }
}
  • G. Bardy, K. Lee, +14 authors J. Ip
  • Published 20 January 2005
  • Medicine
  • The New England journal of medicine
BACKGROUND Sudden death from cardiac causes remains a leading cause of death among patients with congestive heart failure (CHF. [...] Key Method Placebo and amiodarone were administered in a double-blind fashion. The primary end point was death from any cause. RESULTS The median LVEF in patients was 25 percent; 70 percent were in NYHA class II, and 30 percent were in class III CHF. The cause of CHF was ischemic in 52 percent and nonischemic in 48 percent. The median follow-up was 45.5 months. There were 244…Expand
Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial
TLDR
ICD therapy reduced cardiac mortality and sudden death presumed to be ventricular tachyarrhythmic in SCD-HeFT and had no effect on heart failure mortality. Expand
Amiodarone therapy in patients implanted with cardioverter-defibrillator for life-threatening ventricular arrhythmias.
TLDR
The present study could not demonstrate the benefit of amiodarone in ICD patients, probably due to a significant clinical bias exerted in selecting this drug. Expand
Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).
TLDR
Patients with more advanced heart failure have a higher risk of mortality and arrhythmic events than patients with less severe disease, and there is no significant difference in the benefit from ICD therapy among the above subgroups of patients in the Multicenter Automatic Defibrillator Implantation Trial. Expand
Cardiac-resynchronization therapy for mild-to-moderate heart failure.
TLDR
Among patients with NYHA class II or III heart failure, a wide QRS complex, and left ventricular systolic dysfunction, the addition of CRT to an ICD reduced rates of death and hospitalization for heart failure. Expand
Use of implantable cardioverter defibrillator in nonischaemic cardiomyopathy: a U-turn?
TLDR
From a pathophysiological stand point, the occurrence of SCD in patients with heart failure and severe LVSD can be explained by the three determinants of arrhythmogenesis proposed by Philippe Coumel at the end of the last century. Expand
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.
TLDR
In this trial, prophylactic ICD implantation in patients with symptomatic systolic heart failure not caused by coronary artery disease was not associated with a significantly lower long-term rate of death from any cause than was usual clinical care. Expand
Impact of implantable cardioverter defibrillators on survival and recurrent hospitalization in advanced heart failure.
TLDR
Patients with advanced heart failure selected to receive ICDs have better survival trends but shorter time to rehospitalization than patients without I CDs, and benefit appears greater for those with prolonged QRS duration. Expand
Underutilization of Implantable Cardioverter-Defibrillators in Older Patients.
TLDR
The results of the study examining the association between ICD implantation rates and mortality in Medicare beneficiaries treated at US hospitals between 2007 and 2010 found that patients who received an ICD within 1 year were more likely to have presented initially with a STEMI, were younger and male, and had larger infarcts. Expand
Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy
TLDR
A meta-analysis of randomized trials addressed the effect of ICD therapy versus conventional care for primary prevention of death of various causes in patients with ischemic or nonischemic cardiomyopathy, and focused only on primary prevention. Expand
Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
TLDR
Implantable cardioverter-defibrillator therapy did not reduce the risk of sudden cardiac death (or, as a consequence, all-cause death) in HFrEF patients with diabetes, and an ICD reduced therisk of sudden death in patients without diabetes, irrespective of etiology. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.
TLDR
In patients with severe, nonischemic dilated cardiomyopathy who were treated with ACE inhibitors and beta-blockers, the implantation of a cardioverter-defibrillator significantly reduced the risk of sudden death from arrhythmia and was associated with a nonsignificant reduction in the riskof death from any cause. Expand
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.
TLDR
Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival among patients with heart failure, except for a trend toward reduced mortality among those with nonischemic cardiomyopathy. Expand
Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT.
TLDR
Mortality and quality of life in patients with NIDCM and NSVT treated with amiodarone or an ICD are not statistically different and there is a trend towards a more beneficial cost profile and improved arrhythmia-free survival with amioarone therapy. Expand
PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION
TLDR
In patients with a prior myocardial infarction and advanced left ventricular dysfunction, prophylactic implantation of a defibrillator improves survival and should be considered as a recommended therapy. Expand
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
TLDR
A 20% relative risk reduction occurred in all-cause mortality and a 33% reduction occur in arrhythmic mortality with ICD therapy compared with amiodarone; this reduction did not reach statistical significance. Expand
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
TLDR
Among survivors of ventricular fibrillation or sustained ventricular tachycardia causing severe symptoms, the implantable cardioverter-defibrillator is superior to antiarrhythmic drugs for increasing overall survival. Expand
Randomised trial of low-dose amiodarone in severe congestive heart failure
TLDR
Low-dose amiodarone proved to be an effective and reliable treatment, reducing mortality and hospital admission in patients with severe heart failure independently of the presence of complex ventricular arrhythmias. Expand
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
TLDR
The findings do not support the systematic prophylactic use of amiodarone in all patients with depressed left-ventricular function after myocardial infarction, but the lack of proarrhythmia and the reduction in arrhythmic death support the use of the drug in patients for whom antiarrhythmmic therapy is indicated. Expand
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia.
TLDR
A two-sided sequential design with death from any cause as the end point was used and patients were randomly assigned to receive an implanted defibrillator or conventional medical therapy. Expand
The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial
TLDR
For ICD patients, DDDR-70 pacing exhibits no clinical advantage over VVI-40 pacing and may increase CHF and mortality and the DAVID trial sought to measure the impact of dual chamber pacing at 70 bpm vs. ventricular backup pacing. Expand
...
1
2
3
...